Could this new gene-therapy technology help aspergillosis patients?

Hunter syndrome stem cell treatment

Not directly now — but potentially yes in the longer term.

The gene therapy in the BBC story works because Hunter syndrome is caused by a single faulty gene. Doctors can take stem cells, insert a missing gene, and put them back into the body — and the body starts producing the enzyme that was missing.

Aspergillosis is different.
It isn’t caused by a single gene error — it’s caused by:

• An over-reaction of the immune system in ABPA

• Underlying lung damage or structural disease in CPA

• A combination of genetics, environment, allergens and fungal exposure

• Sometimes problems with mucus clearance

So gene therapy is not close to being used for aspergillosis in the same direct way.

But here’s why the technology could help in the future

The breakthrough still matters because it shows what is becoming possible:

1. Fixing immune-pathway problems

Some people with ABPA or severe asthma have genetic variants in pathways such as:

• IL-4 / IL-5 / IgE regulation

• Mucus clearance

• Immune “switch-off” mechanisms

In the future, gene therapy could correct faulty immune pathways so the lungs stop over-reacting to Aspergillus.

2. Improving mucus-clearance biology

A big part of aspergillosis is mucus sticking in the airways. If gene therapy can one day boost the function of cilia or mucus-clearing enzymes, that would be a major benefit.

3. Helping people born with lung-structure problems

Some patients develop aspergillosis because they were born with subtle airway abnormalities or genetic bronchiectasis tendencies. Future gene therapies might stabilise or prevent these problems.

4. Fungal infection + rare-disease overlaps

Some immunodeficiency disorders (e.g., CARD9 deficiency) lead to severe fungal infections. This type of therapy is much closer to helping those patients already — because those are single-gene defects.

Realistic timeline

For ABPA or CPA specifically:

• Short term (0–10 years): No direct gene therapy.

• Medium term (10–20 years): Possible targeted immune-pathway correction for asthma/ABPA.

• Long term (20+ years): Potential lung-repair gene therapies, airway-regeneration therapies, or personalised immune-modifying gene treatments.

So this breakthrough doesn’t change aspergillosis care today — but it shows that the tools are coming that could one day target immune-driven diseases much more precisely.